Published in Front Immunol on January 10, 2013
Engineering an effective immune adjuvant by designed control of shape and crystallinity of aluminum oxyhydroxide nanoparticles. ACS Nano (2013) 0.99
The use of self-adjuvanting nanofiber vaccines to elicit high-affinity B cell responses to peptide antigens without inflammation. Biomaterials (2013) 0.94
Advances in aluminum hydroxide-based adjuvant research and its mechanism. Hum Vaccin Immunother (2015) 0.89
Polyionic vaccine adjuvants: another look at aluminum salts and polyelectrolytes. Clin Exp Vaccine Res (2015) 0.89
Adjuvants for vaccines to drugs of abuse and addiction. Vaccine (2014) 0.87
Unequivocal identification of intracellular aluminium adjuvant in a monocytic THP-1 cell line. Sci Rep (2014) 0.87
TLR9 and STING agonists synergistically induce innate and adaptive type-II IFN. Eur J Immunol (2015) 0.85
Boosting vaccine efficacy the natural (killer) way. Trends Immunol (2015) 0.82
Adeno-associated virus-like particles as new carriers for B-cell vaccines: testing immunogenicity and safety in BALB/c mice. Viral Immunol (2014) 0.81
Vaccine adjuvants as potential cancer immunotherapeutics. Int Immunol (2016) 0.80
The mechanisms of action of vaccines containing aluminum adjuvants: an in vitro vs in vivo paradigm. Springerplus (2015) 0.80
A new immunization and treatment strategy for mouse mammary tumor virus (MMTV) associated cancers. Oncotarget (2016) 0.79
Aluminum hydroxide influences not only the extent but also the fine specificity and functional activity of antibody responses to tick-borne encephalitis virus in mice. J Virol (2013) 0.78
Toward understanding the mechanism underlying the strong adjuvant activity of aluminum salt nanoparticles. Vaccine (2016) 0.77
Aluminium in Allergies and Allergen immunotherapy. World Allergy Organ J (2015) 0.77
Use of Phage Display technology in development of canine visceral leishmaniasis vaccine using synthetic peptide trapped in sphingomyelin/cholesterol liposomes. Parasit Vectors (2015) 0.77
Insight into the cellular fate and toxicity of aluminium adjuvants used in clinically approved human vaccinations. Sci Rep (2016) 0.76
Evaluation of Borrelia burgdorferi BbHtrA Protease as a Vaccine Candidate for Lyme Borreliosis in Mice. PLoS One (2015) 0.75
T Cell Epitope-Containing Domains of Ragweed Amb a 1 and Mugwort Art v 6 Modulate Immunologic Responses in Humans and Mice. PLoS One (2017) 0.75
Immunogenicity of a Bivalent Adjuvanted Glycoconjugate Vaccine against Salmonella Typhimurium and Salmonella Enteritidis. Front Immunol (2017) 0.75
Co-Administration of Lipid Nanoparticles and Sub-Unit Vaccine Antigens Is Required for Increase in Antigen-Specific Immune Responses in Mice. Vaccines (Basel) (2016) 0.75
Development of Improved Vaccine Adjuvants Based on the Saponin Natural Product QS-21 through Chemical Synthesis. Acc Chem Res (2016) 0.75
Effects of MF59 Adjuvant on Induction of Isotype-Switched IgG Antibodies and Protection after Immunization with T-Dependent Influenza Virus Vaccine in the Absence of CD4+ T Cells. J Virol (2016) 0.75
Generation of protective immunity against Orientia tsutsugamushi infection by immunization with a zinc oxide nanoparticle combined with ScaA antigen. J Nanobiotechnology (2016) 0.75
Rehmannia glutinosa polysaccharide liposome as a novel strategy for stimulating an efficient immune response and their effects on dendritic cells. Int J Nanomedicine (2016) 0.75
Use of adjuvants for immunotherapy. Hum Vaccin Immunother (2017) 0.75
Safety and efficiency of active immunization with detoxified antigen against scorpion venom: side effect evaluation. Inflamm Res (2017) 0.75
Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol (1986) 35.41
Targeted disruption of the MyD88 gene results in loss of IL-1- and IL-18-mediated function. Immunity (1998) 18.12
Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization. Nat Immunol (2008) 16.65
The inflammasomes: guardians of the body. Annu Rev Immunol (2009) 12.89
Differentiation of effector CD4 T cell populations (*). Annu Rev Immunol (2010) 11.80
Bcl6 and Blimp-1 are reciprocal and antagonistic regulators of T follicular helper cell differentiation. Science (2009) 9.22
Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants. Nature (2008) 9.16
Molecular identification of a danger signal that alerts the immune system to dying cells. Nature (2003) 8.90
Bcl6 mediates the development of T follicular helper cells. Science (2009) 8.50
The transcriptional repressor Bcl-6 directs T follicular helper cell lineage commitment. Immunity (2009) 7.69
Toll-like receptors control activation of adaptive immune responses. Nat Immunol (2001) 7.54
Adjuvant-enhanced antibody responses in the absence of toll-like receptor signaling. Science (2006) 6.47
GAD treatment and insulin secretion in recent-onset type 1 diabetes. N Engl J Med (2008) 5.74
Alum adjuvant boosts adaptive immunity by inducing uric acid and activating inflammatory dendritic cells. J Exp Med (2008) 5.42
Vaccine adjuvants: putting innate immunity to work. Immunity (2010) 5.02
The Nlrp3 inflammasome is critical for aluminium hydroxide-mediated IL-1beta secretion but dispensable for adjuvant activity. Eur J Immunol (2008) 4.72
Cutting edge: inflammasome activation by alum and alum's adjuvant effect are mediated by NLRP3. J Immunol (2008) 4.60
ATP activates a reactive oxygen species-dependent oxidative stress response and secretion of proinflammatory cytokines in macrophages. J Biol Chem (2006) 4.33
MHC class II-dependent basophil-CD4+ T cell interactions promote T(H)2 cytokine-dependent immunity. Nat Immunol (2009) 4.28
Phagocyte partnership during the onset and resolution of inflammation. Nat Rev Immunol (2010) 4.07
Interleukin-17A mediates acquired immunity to pneumococcal colonization. PLoS Pathog (2008) 4.05
HSP70 as endogenous stimulus of the Toll/interleukin-1 receptor signal pathway. J Biol Chem (2002) 4.03
Diphtheria Immunization with Fluid Toxoid and Alum-Precipitated Toxoid. Am J Public Health Nations Health (1942) 3.95
Cross-presentation by dendritic cells. Nat Rev Immunol (2012) 3.95
Basophils contribute to T(H)2-IgE responses in vivo via IL-4 production and presentation of peptide-MHC class II complexes to CD4+ T cells. Nat Immunol (2009) 3.82
Basophils function as antigen-presenting cells for an allergen-induced T helper type 2 response. Nat Immunol (2009) 3.79
Advantages of aluminium hydroxide adsorbed combined diphtheria, tetanus, and pertussis vaccines for the immunization of infants. Br Med J (1969) 3.69
Cutting edge: alum adjuvant stimulates inflammatory dendritic cells through activation of the NALP3 inflammasome. J Immunol (2008) 3.66
Towards an understanding of the adjuvant action of aluminium. Nat Rev Immunol (2009) 3.51
The sterile inflammatory response. Annu Rev Immunol (2010) 3.45
The perfect mix: recent progress in adjuvant research. Nat Rev Microbiol (2007) 3.44
Signal 3 determines tolerance versus full activation of naive CD8 T cells: dissociating proliferation and development of effector function. J Exp Med (2003) 3.21
Aluminum hydroxide adjuvants activate caspase-1 and induce IL-1beta and IL-18 release. J Immunol (2007) 3.17
Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: a randomised double-blind trial. Lancet (2011) 3.13
Th1-Th17 cells mediate protective adaptive immunity against Staphylococcus aureus and Candida albicans infection in mice. PLoS Pathog (2009) 3.05
Aluminium compounds for use in vaccines. Immunol Cell Biol (2004) 2.99
CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen. J Immunol (1998) 2.93
Inflammatory dendritic cells--not basophils--are necessary and sufficient for induction of Th2 immunity to inhaled house dust mite allergen. J Exp Med (2010) 2.91
Alum interaction with dendritic cell membrane lipids is essential for its adjuvanticity. Nat Med (2011) 2.82
F-actin is an evolutionarily conserved damage-associated molecular pattern recognized by DNGR-1, a receptor for dead cells. Immunity (2012) 2.72
Generation of CD8 T cell memory is regulated by IL-12. J Immunol (2007) 2.69
An unexpected role for uric acid as an inducer of T helper 2 cell immunity to inhaled antigens and inflammatory mediator of allergic asthma. Immunity (2011) 2.57
Vaccine adjuvants alum and MF59 induce rapid recruitment of neutrophils and monocytes that participate in antigen transport to draining lymph nodes. Vaccine (2011) 2.53
AS04, an aluminum salt- and TLR4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity. J Immunol (2009) 2.49
Promotion of B cell immune responses via an alum-induced myeloid cell population. Science (2004) 2.47
Alum induces innate immune responses through macrophage and mast cell sensors, but these sensors are not required for alum to act as an adjuvant for specific immunity. J Immunol (2009) 2.47
Uptake of particulate vaccine adjuvants by dendritic cells activates the NALP3 inflammasome. Proc Natl Acad Sci U S A (2009) 2.42
DNA released from dying host cells mediates aluminum adjuvant activity. Nat Med (2011) 2.41
Stability of protein pharmaceuticals: an update. Pharm Res (2010) 2.38
Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only. Vaccine (2006) 2.37
Aluminum compounds as vaccine adjuvants. Adv Drug Deliv Rev (1998) 2.36
Basophils orchestrate chronic allergic dermatitis and protective immunity against helminths. Immunity (2010) 2.35
Subcutaneous versus intramuscular injection for booster DT vaccination of adolescents. Vaccine (1999) 2.30
Adverse events after immunisation with aluminium-containing DTP vaccines: systematic review of the evidence. Lancet Infect Dis (2004) 2.25
Molecular and cellular signatures of human vaccine adjuvants. Proc Natl Acad Sci U S A (2008) 2.02
CPG 7909, an immunostimulatory TLR9 agonist oligodeoxynucleotide, as adjuvant to Engerix-B HBV vaccine in healthy adults: a double-blind phase I/II study. J Clin Immunol (2004) 1.98
Aluminum salts in vaccines--US perspective. Vaccine (2002) 1.97
The dendritic cell receptor Clec9A binds damaged cells via exposed actin filaments. Immunity (2012) 1.89
Modulation of the human immune response by the non-toxic and non-pyrogenic adjuvant aluminium hydroxide: effect on antigen uptake and antigen presentation. Clin Exp Immunol (1985) 1.88
Relationship between physical and chemical properties of aluminum-containing adjuvants and immunopotentiation. Expert Rev Vaccines (2007) 1.86
Activation of dendritic cells and induction of CD4(+) T cell differentiation by aluminum-containing adjuvants. Vaccine (2007) 1.76
The adjuvants aluminum hydroxide and MF59 induce monocyte and granulocyte chemoattractants and enhance monocyte differentiation toward dendritic cells. J Immunol (2008) 1.71
Silica crystals and aluminum salts regulate the production of prostaglandin in macrophages via NALP3 inflammasome-independent mechanisms. Immunity (2011) 1.65
Comparison of fibrosarcomas that developed at vaccination sites and at nonvaccination sites in cats: 239 cases (1991-1992). J Am Vet Med Assoc (1994) 1.62
In interleukin-4-deficient mice, alum not only generates T helper 1 responses equivalent to freund's complete adjuvant, but continues to induce T helper 2 cytokine production. Eur J Immunol (1996) 1.59
Specific immunotherapy in honeybee venom allergy: a comparative study using aqueous and aluminium hydroxide adsorbed preparations. Allergy (2004) 1.56
Pivotal advance: eosinophils mediate early alum adjuvant-elicited B cell priming and IgM production. J Leukoc Biol (2008) 1.55
Stimulation of Th1-polarizing cytokines, C-C chemokines, maturation of dendritic cells, and adjuvant function by the peptide binding fragment of heat shock protein 70. J Immunol (2002) 1.54
Postvaccinal sarcomas in the cat: epidemiology and electron probe microanalytical identification of aluminum. Cancer Res (1992) 1.53
Role of aluminum-containing adjuvants in antigen internalization by dendritic cells in vitro. Vaccine (2005) 1.51
The immunobiology of aluminium adjuvants: how do they really work? Trends Immunol (2010) 1.45
Neutrophils influence the level of antigen presentation during the immune response to protein antigens in adjuvants. J Immunol (2010) 1.43
Saponin adjuvant enhancement of antigen-specific immune responses to an experimental HIV-1 vaccine. J Immunol (1992) 1.42
Anthrax vaccine: immunogenicity and safety of a dose-reduction, route-change comparison study in humans. Vaccine (2002) 1.41
Aluminum hydroxide adjuvant induces macrophage differentiation towards a specialized antigen-presenting cell type. Vaccine (2004) 1.36
The Common vaccine adjuvant aluminum hydroxide up-regulates accessory properties of human monocytes via an interleukin-4-dependent mechanism. Infect Immun (2001) 1.30
Antigen depot is not required for alum adjuvanticity. FASEB J (2011) 1.28
Alum adjuvant: some of the tricks of the oldest adjuvant. J Med Microbiol (2011) 1.20
Effects of adsorption to aluminum salt adjuvants on the structure and stability of model protein antigens. J Biol Chem (2005) 1.19
Relationship between the strength of antigen adsorption to an aluminum-containing adjuvant and the immune response. Vaccine (2007) 1.19
Vaccine adjuvants aluminum and monophosphoryl lipid A provide distinct signals to generate protective cytotoxic memory CD8 T cells. Proc Natl Acad Sci U S A (2011) 1.18
Vaccine adjuvants. Rev Infect Dis (1980) 1.17
Novel cellular and molecular mechanisms of induction of immune responses by aluminum adjuvants. Trends Pharmacol Sci (2009) 1.16
Degree of antigen adsorption in the vaccine or interstitial fluid and its effect on the antibody response in rabbits. Vaccine (2001) 1.16
Antigen processing and remodeling of the endosomal pathway: requirements for antigen cross-presentation. Front Immunol (2012) 1.15
Prevention and treatment of papillomavirus-related cancers through immunization. Annu Rev Immunol (2011) 1.15
ATP release and purinergic signaling: a common pathway for particle-mediated inflammasome activation. Cell Death Dis (2012) 1.13
Potentiation of the immune response to non-adsorbed antigens by aluminum-containing adjuvants. Vaccine (2006) 1.11
Formulation of vaccines containing CpG oligonucleotides and alum. J Immunol Methods (2007) 1.11
Eosinophil response to alum adjuvants: involvement of T cells in non-antigen-dependent mechanisms. Proc Soc Exp Biol Med (1977) 1.11
Local tissue irritating effects and adjuvant activities of calcium phosphate and aluminium hydroxide with different physical properties. Vaccine (1997) 1.10
A study of trends in upper arm soft tissue sarcomas in the state of Connecticut following the introduction of alum-absorbed allergenic extract. Ann Allergy (1978) 1.07
Unexpectedly high incidence of persistent itching nodules and delayed hypersensitivity to aluminium in children after the use of adsorbed vaccines from a single manufacturer. Vaccine (2003) 1.07
Helios is associated with CD4 T cells differentiating to T helper 2 and follicular helper T cells in vivo independently of Foxp3 expression. PLoS One (2011) 1.06
Aluminium assay and evaluation of the local reaction at several time points after intramuscular administration of aluminium containing vaccines in the Cynomolgus monkey. Vaccine (2005) 1.05
Immunogenicity in mice of anthrax recombinant protective antigen in the presence of aluminum adjuvants. Vaccine (2005) 1.04
T-helper 1 and T-helper 2 adjuvants induce distinct differences in the magnitude, quality and kinetics of the early inflammatory response at the site of injection. Immunology (2009) 1.04
An overview of the pharmacokinetics and pharmacodynamics of efalizumab: a monoclonal antibody approved for use in psoriasis. J Clin Pharmacol (2006) 1.03
GAD-alum treatment induces GAD65-specific CD4+CD25highFOXP3+ cells in type 1 diabetic patients. Clin Immunol (2010) 1.02